ARCE Tx to Advance ARD103 into the Clinic after Promising Preclinical Results in AML; NKGen Biotech and Affimed not Proceeding to Ph2 Trial Combining AFM24 and SNK01 in Solid Tumors; ASCO Breakthrough 2023 Analysis
Here is a brief preview of this blast: ASCO Breakthrough 2023 Analysis: ARCE Tx reported preclinical updates from ARD103, a CLL-1 CAR-T manufactured with its DashCAR technology, while NKGen biotech and Affimed presented initial results of their collaboration to evaluate SNK01 (autologous NK cells) in combination with AFM24 (EGFR x CD16 bispecific NK cell engager) in advanced or metastatic EGFR+ solid tumors.